SCHEMBL12488697

SCHEMBL12488697

OB(O)c1ccc2[nH]cnc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.44
MAPT P10636 3/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PRKCI P41743 1/20 0.40
RAD52 P43351 1/20 0.39
MMP12 P39900 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
TTR P02766 1/20 0.36
CYP3A4 P08684 1/20 0.36
NAMPT P43490 1/20 0.36
XDH P47989 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29951513 0.98 ENPP2 (0.43) ENPP2MAPTKDM4EALDH1A1APEX1
SCHEMBL29951105 0.85 PRKCI (0.53) ENPP2MAPTKDM4EALDH1A1APEX1
SCHEMBL4840069 0.85 PRKCI (0.53) ENPP2MAPTKDM4EALDH1A1APEX1
SCHEMBL8210731 0.75 PARP1 (0.58) ALDH1A1SMN1; SMN2
SCHEMBL29953175 0.75 ENPP2 (0.39) ENPP2MAPTALDH1A1HDAC6HPGD
SCHEMBL2723600 0.75 ENPP2 (0.39) ENPP2MAPTALDH1A1HDAC6HPGD
SCHEMBL2361665 0.74 MMP12 (0.34) MAPTKDM4EALDH1A1APEX1RECQL
Phenylboronic Acid SCHEMBL28818194 0.74 CA4 (0.50) ENPP2MAPTKDM4EALDH1A1PRKCI
SCHEMBL352025 0.74 LMNA (0.55) ENPP2MAPTKDM4EALDH1A1APEX1
SCHEMBL30798705 0.73 MMP12 (0.45) MAPTKDM4EALDH1A1APEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 US disclosed
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof THE UAB RESEARCH FOUNDATION (US) 2025-10-07 US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 EP disclosed
EP-3321268-B1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2025-06-04 EP disclosed
US-20250145625-A1 PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-05-08 US disclosed
EP-4458827-A1 PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2024-11-06 EP disclosed
CN-114555588-B Quinazoline compounds as AXL inhibitors 南京正大天晴制药有限公司 2024-08-06 CN disclosed
CN-118414337-A Pyrazolopyrimidine derivative and anticancer pharmaceutical composition containing same as active ingredient 韩国化学研究院 2024-07-30 CN disclosed
US-20240101577-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. 2024-03-28 US disclosed
CN-117720472-A Benzimidazole compound, and preparation method and application thereof 苏州沪云新药研发股份有限公司 2024-03-19 CN disclosed
US-20140371199-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-12-18 US disclosed
US-8912173-B2 Substituted quinolines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-12-16 US disclosed
US-20140221387-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2014-08-07 US disclosed
EP-2736886-A1 SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2014-06-04 EP disclosed
WO-2014031784-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS ALIOS BIOPHARMA, INC. (US) 2014-02-27 WO disclosed
EP-2684167-A2 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES Eutropics Pharmaceuticals, Inc. (US) 2014-01-15 EP disclosed
WO-2013147711-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-10-03 WO disclosed
WO-2013014060-A1 SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 WO disclosed
US-20130029949-A1 Substituted Quinolines and Their Use As Medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
WO-2012122370-A2 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145625-A1 PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT DPYD, TP53, WASHC5 ENPP2 3533/4885MAPT 2312/4885KDM4E 1635/4885
US-20140221387-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES BCL3, MCL1, BCL6 ENPP2 156/4885MAPT 3621/4885KDM4E 486/4885
US-20240101577-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS PTPN18, PTPN1, PTPRJ ENPP2 162/4885MAPT 3798/4885KDM4E 979/4885
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 ENPP2 3779/4885MAPT 4813/4885KDM4E 1112/4885
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof HNRNPR, HNRNPAB, RBM3 ENPP2 2704/4885MAPT 911/4885KDM4E 3026/4885
US-20130029949-A1 Substituted Quinolines and Their Use As Medicaments QARS1, RECQL, CYP3A7 ENPP2 2251/4885MAPT 3662/4885KDM4E 2395/4885
US-20140371199-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF MAPKAPK2, MKNK2, MAP4K2 ENPP2 1198/4885MAPT 525/4885KDM4E 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.